Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Myriad Genetics Inc MYGN

Healthcare Biotechnology
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has... see more

Recent & Breaking News (NDAQ:MYGN)

Myriad Announces Leadership Transition

GlobeNewswire February 6, 2020

Myriad Genetics Reports Fiscal Second-Quarter 2020 Financial Results

GlobeNewswire February 6, 2020

Myriad to Announce Fiscal Second-Quarter 2020 Financial Results on February 6, 2020

GlobeNewswire January 30, 2020

Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Cancer

GlobeNewswire January 22, 2020

Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Metastatic Castration-resistant Prostate Cancer

GlobeNewswire January 21, 2020

Dr. Thomas P. Slavin Named Senior Vice President of Medical Affairs for Myriad Oncology

GlobeNewswire January 14, 2020

Myriad Genetics to Present at the J.P. Morgan 2020 Healthcare Conference

GlobeNewswire January 6, 2020

New Publication Demonstrates GeneSight® Improved All Clinical Outcomes Using HAM-D6 Analysis in Large Prospective GUIDED Study

GlobeNewswire January 6, 2020

INVESTOR ALERT: Kirby McInerney LLP Launches Investigation of Myriad Genetics (MYGN) for Possible Breaches of Fiduciary Duty by Certain Officers and Directors

Business Wire December 30, 2019

Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreatic Cancer

GlobeNewswire December 30, 2019

Myriad Genetics' Board Member, S. Louise Phanstiel, Recognized by WomenInc. Magazine in 2019 List of Most Influential Corporate Directors

GlobeNewswire December 19, 2019

Myriad's Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer Genes

GlobeNewswire December 14, 2019

Myriad's Prequel(TM) Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening

GlobeNewswire December 4, 2019

Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium

GlobeNewswire December 3, 2019

CLASS ACTION UPDATE for OSTK, MYGN and GRUB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

ACCESSWIRE IA November 26, 2019

FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm

ACCESSWIRE IA November 26, 2019

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SEE, MYGN, ZEN and YJ

GlobeNewswire November 26, 2019

MYGN DEADLINE TODAY: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Myriad Genetics (MYGN) Investors of Today's Deadline to Move for Lead Plaintiff

ACCESSWIRE IA November 26, 2019

FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm

ACCESSWIRE IA November 25, 2019

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of MYGN, CC and ET

ACCESSWIRE IA November 25, 2019